Serafin Morales Murillo

Baselga, J; Morales, SM; Awada, A; Blum, JL; Tan, AR; Ewertz, M; Cortes, J; Moy, B; Ruddy, KJ; Haddad, T; Ciruelos, EM; Vuylsteke, P; Ebbinghaus, S; Im, E; Eaton, L; Pathiraja, K; Gause, C; Mauro, D; Jones, MB; Rugo, HS

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

BREAST CANCER RESEARCH AND TREATMENT 163 535-544. 01/06/2017.

[doi:10.1007/s10549-017-4199-3]

Mateo, F; Arenas, EJ; Aguilar, H; Serra-Musach, J; de Garibay, GR; Boni, J; Maicas, M; Du, S; Iorio, F; Herranz-Ors, C; Islam, A; Prado, X; Llorente, A; Petit, A; Vidal, A; Catala, I; Soler, T; Venturas, G; Rojo-Sebastian, A; Serra, H; Cuadras, D; Blanco, I; Lozano, J; Canals, F; Sieuwerts, AM; de Weerd, V; Look, MP; Puertas, S; Garcia, N; Perkins, AS; Bonifaci, N; Skowron, M; Gomez-Baldo, L; Hernandez, V; Martinez-Aranda, A; Martinez-Iniesta, M; Serrat, X; Ceron, J; Brunet, J; Barretina, MP; Gil, M; Falo, C; Fernandez, A; Morilla, I; Pernas, S; Pla, MJ; Andreu, X; Segui, MA; Ballester, R; Castella, E; Nellist, M; Morales, S; Valls, J; Velasco, A; Matias-Guiu, X; Figueras, A; Sanchez-Mut, JV; Sanchez-Cespedes, M; Cordero, A; Gomez-Miragaya, J; Palomero, L; Gomez, A; Gajewski, TF; Cohen, EEW; Jesiotr, M; Bodnar, L; Quintela-Fandino, M; Lopez-Bigas, N; Valdes-Mas, R; Puente, XS; Viñals F; Casanovas, O; Graupera, M; Hernandez-Losa, J; Ramón Y Cajal S; Garcia-Alonso, L; Saez-Rodriguez, J; Esteller, M; Sierra, A; Martin-Martin, N; Matheu, A; Carracedo, A; Gonzalez-Suarez, E; Nanjundan, M; Cortes, J; Lazaro, C; Odero, MD; Martens, JWM; Moreno-Bueno, G; Barcellos-Hoff, MH; Villanueva, A; Gomis, RR; Pujana, MA

Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

ONCOGENE 36 2737-2749. 11/05/2017.

[doi:10.1038/onc.2016.427]

Llombart-Cussac, A; Cortes, J; Pare, L; Galvan, P; Bermejo, B; Martinez, N; Vidal, M; Pernas, S; Lopez, R; Muñoz M; Nuciforo, P; Morales, S; Oliveira, M; de la Peña L; Pelaez, A; Prat, A

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

LANCET ONCOLOGY 18 545-554. 01/04/2017.

[doi:10.1016/S1470-2045(17)30021-9]

Fernandez-Martinez, A; Pascual, T; Perrone, G; Morales, S; de la Haba, J; Gonzalez-Rivera, M; Galvan, P; Zalfa, F; Amato, M; Gonzalez, L; Prats, M; Rojo, F; Manso, L; Pare, L; Alonso, I; Albanell, J; Vivancos, A; Gonzalez, A; Matito, J; Gonzalez, S; Fernandez, P; Adamo, B; Muñoz M; Viladot, M; Font, C; Aya, F; Vidal, M; Caballero, R; Carrasco, E; Altomare, V; Tonini, G; Prat, A; Martin, M

Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

Oncotarget 8 21930-21937. 28/03/2017.

[doi:10.18632/oncotarget.15748]

Gasol Cudos, A.; Morales Murillo, S.; Panades Siurana, M. J.; Vilardell Villellas, F.; Canosa Morales, C.; Mele Olive, J.; Iglesias Martinez, E.; Salud Salvia, A.

Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution

BREAST 32 92-93. 01/03/2017.

Prat, A.; Ortega, V.; Villagrasa, P.; Pare, L.; Galvan, P.; Oliveira, M.; Nuciforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; Gonzalez, R.; Manso, L.; Martinez, J.; Llombart, A.; De la Pena, L.; Di Cosimo, S.; Rubio, I. T.; Harbeck, N.; Baselga, J.; Cortes, J.

Efficacy and gene expression results from SOLTI1007 NEOERIBULIN phase II clinical trial in HER2-negative early breast cancer

CANCER RESEARCH 77 -. 01/02/2017.

[doi:10.1158/1538-7445.SABCS16-P1-09-09]

Gavila, J.; Perez-Garcia, J.; Calvo, I.; Ciruelos, E.; Munoz, M.; Virizuela, J. A.; Ruiz, I.; Andres, R.; Morales, S.; Perello, A.; Sanchez, P.; Garcia-Saenz, J. A.; Quero Guillen, J. C.; Gonzalez-Santiago, S.; Garau Llinas, I.; Gonzalez-Martin, A.; Sanchez de Ibarguen, B. Cantos; Zaragoza, K.; de la Pena, L.; Llombart-Cussac, A.; Oliveira, M.

Neoadjuvant non-pegylated liposomal doxorubicin plus paclitaxel, trastuzumab and pertuzumab in patients with HER2+breast cancer - Final results of the SOLTI OPTI-HER HEART study

CANCER RESEARCH 77 -. 01/02/2017.

[doi:10.1158/1538-7445.SABCS16-P4-21-05]

Aparicio, AP; Castan, JC; Pare, L; Galvan, P; Bermejo, B; Martinez, N; Vidal, M; Pernas, S; Lopez, R; Munoz, M; Nuciforo, P; Fasani, R; Morales, S; Oliveira, M; de la Pena, L; Pelaez, A; Llombart, A

PAM50 intrinsic subtype as a predictor of pathological complete response following neoadjuvant dual HER2 blockade without chemotherapy in HER2-positive breast cancer: First results of the PAMELA clinical trial

CANCER RESEARCH 77 -. 01/02/2017.

[doi:10.1158/1538-7445.SABCS16-S3-03]

Martin, M; Kahan, Z; Carrasco, E; Bartlett, CH; Casas, M; Gil-Gil, M; Munoz, M; Ciruelos, EM; Ruiz-Borrego, M; Margeli, M; Anton, A; Bermejo, B; Morales, S; Gal-Yam, E; Koehler, M; Garcia-Saenz, JA; de la Haba, J; Chacon, I; Zielinski, C

Phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. "The PEARL study" (GEICAM/2013-02)

CANCER RESEARCH 77 -. 01/02/2017.

[doi:10.1158/1538-7445.SABCS16-OT2-01-06]

Krop, IE; Mayer, IA; Ganju, V; Dickler, M; Johnston, S; Morales, SN; Yardley, DA; Melichar, B; Forero-Torres, A; Lee, SC; de Boer, R; Petrakova, K; Vallentin, S; Perez, EA; Piccart, M; Ellis, M; Winer, E; Gendreau, S; Derynck, M; Lackner, M; Levy, G; Qiu, JH; He, J; Schmid, P

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

LANCET ONCOLOGY 17 811-821. 01/06/2016.

[doi:10.1016/S1470-2045(16)00106-6]

Llombart-Cussac, A; Ramos, M; Dalmau, E; Garcia-Saenz, JA; Gonzalez-Farre, X; Murillo, L; Calvo, L; Morales, S; Carañana V; Gonzalez, A; Fernandez-Morales, LA; Moreno, F; Casas, MI; Angulo, MD; Camara, MC; Garcia-Mace, AI; Carrasco, E; Jara-Sanchez, C

Incidence of chemotherapy-induced nausea and vomiting associated with docetaxel and cyclophosphamide in early breast cancer patients and aprepitant efficacy as salvage therapy. Results from the Spanish Breast Cancer Group/2009-02 study

EUROPEAN JOURNAL OF CANCER 58 122-129. 01/05/2016.

[doi:10.1016/j.ejca.2016.01.015]

Gavilá, J.; Lopez-Tarruella, S.; Saura, C.; Muñoz, M.; Oliveira, M.; De la Cruz-Merino, L.; Morales, S.; Alvarez, I.; Virizuela, J.A.; Martin, M.

SEOM clinical guidelines in metastatic breast cancer 2015

CLINICAL & TRANSLATIONAL ONCOLOGY 17 946-955. 01/12/2015.

[doi:10.1007/s12094-015-1476-7]